Full history for every metric is available with a Kvantra account

Stock profile
Viatris Inc. logo

Viatris Inc. (VTRS)

Country: United States of AmericaSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
7.1
Market cap
22.5B
Currency USD
KvantraRankAbout85
IValue96
IIQuality67
IIIMomentum94
Current price
19.63 USD-1.26%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$bn11.917.916.315.414.714.314.714.8
Operating profit$bn-2.66-
Net profit$bn-0.67-1.272.080.05-0.63-3.51-2.99
EPS reported$-3.00-
Operating cashflow per share$1.982.16
Capex per share$0.320.39
FCF per share$1.651.78
Free cash flow$bn1.942.04
Net debt$bn13.211.7
Book value equity$bn14.713.7
Book value per share$12.5711.91
Number of sharesm1,170.71,148.6
DPS (TTM paid)$0.480.48

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx--
P/B LTMx0.991.64
P/S LTMx1.021.53
P/FCF LTMx7.5211.02
EV/EBITDA LTMx-70.6311.98
EV/Sales LTMx1.952.32
Earnings Yield LTM%-24.12%-2.70%
FCF Yield%13.29%9.07%
Quality
ROE%-23.89%-4.24%
ROIC%-7.95%-0.26%
Operating margin%-18.62%-0.53%
Gross margin%35.06%35.22%
FCF/Sales%13.55%13.86%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%-2.98%+4.27%
Net Income Growth YoY%--
FCF Growth%-2.01%+27.66%
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%3.85%2.45%
Dividend Growth%0.00%0.00%
Payout Ratio%--
FCF/Debtx0.130.15
Net Debt/EBITDAx-33.774.13
EBIT/Net interestx-5.65-0.16
Net debt/market cap%90.89%51.91%
Net debt/Equityx0.900.85
Gross debt/equityx1.000.99

ETFs that hold Viatris

FundTickerPosition#Weight
Schwab U.S. Mid-Cap ETFSCHM50.49%
iShares MSCI World Small Cap UCITS ETFIUSN.DE30.23%
WisdomTree U.S. MidCap Dividend FundDON21.61%
iShares Russell 2500 ETFSMMD20.35%
iShares U.S. Pharmaceuticals ETFIHE44.88%
State Street SPDR MSCI World Small Cap UCITS ETF (Acc)WDSC.L40.23%
Davis Select U.S. Equity ETFDUSA55.74%
Invesco S&P 500 Equal Weight Health Care ETFRSPH71.86%
Nuveen ESG Small-Cap ETFNUSC11.34%
First Trust Nasdaq Pharmaceuticals ETFFTXH64.22%

Funds with Viatris among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price19.63 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Viatris Inc. (VTRS)

VTRS · NASDAQ · Healthcare
19.63 USD-1.26%
Sign up to track this stock
Benchmarks
KvantraRank85
Market cap22.5B
P/E NTM7.1
P/E TTMN/A
KvantraRank?85 / 100
Value
96
Quality
67
Momentum
94
Financialsin USD
20242025TTM2026E
ETFs that hold Viatris
FundTickerPosition#Weight
Schwab U.S. Mid-Cap ETFSCHM50.49%
iShares MSCI World Small Cap UCITS ETFIUSN.DE30.23%
WisdomTree U.S. MidCap Dividend FundDON21.61%
iShares Russell 2500 ETFSMMD20.35%
iShares U.S. Pharmaceuticals ETFIHE44.88%
State Street SPDR MSCI World Small Cap UCITS ETF (Acc)WDSC.L40.23%
Davis Select U.S. Equity ETFDUSA55.74%
Invesco S&P 500 Equal Weight Health Care ETFRSPH71.86%
Nuveen ESG Small-Cap ETFNUSC11.34%
First Trust Nasdaq Pharmaceuticals ETFFTXH64.22%

Funds with Viatris among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current19.63 USD
Upside
Price consensus
Last year average price target
Current price19.63 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

IndustryDrug Manufacturers - Specialty & Generic
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free